MoonLake Immunotherapeutics
NASDAQ:MLTX

  • LAST PRICE
    48.8300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    98.0000/ 1
  • Open / Previous Close
    --- / 48.8300
  • Day Range
    ---
  • 52 Week Range
    37.3450
    64.9800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: MLTX

      For PsA, sonelokimab is being assessed in the Phase 3 trials, IZAR-1 and IZAR-2, following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody(R) sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key outcomes, including up to 61% of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving ACR50 response compared to those on placebo at week 12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.

  • Nov 8, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 9:30AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: MLTX
      09:30 AM EST, 11/07/2024 (MT Newswires) -- MoonLake Immunotherapeutics (MLTX) reported a Q3 net loss Thursday of $0.56 per diluted share, widening from a loss of $0.18 a year earlier. Analysts polled by Capital IQ expected a loss of $0.43. The clini...

    • 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: MLTX

      (Amounts in USD, except share data)
      September 30, 2024 (Unaudited) December 31.2023 Current assets Cash and cash equivalents $ 375,656,291 $ 451,169,337 Short-term marketable debt securities 118,268,400 59,838,900 Other receivables 2,407,062 1,056,862 Prepaid expenses - current 15,984,425 2,102,203 Total current assets 512,316,178 514,167,302 --------------------- --------------------- Non-current assets Operating lease right-of-use assets 3,251,197 3,628,480 Property and equipment, net 581,378 320,865 Prepaid expenses - non-current 2,064,575 8,423,468 Total non-current assets 5,897,150 12,372,813 --------------------- --------------------- Total assets $ 518,213,328 $ 526,540,115 ===================== ===================== Current liabilities Trade and other payables $ 10,710,603 $ 1,837,684 Short-term portion of operating lease liabilities 1,444,893 1,197,876 Accrued expenses and other current liabilities 7,925,524 6,930,120 Total current liabilities 20,081,020 9,965,680 --------------------- --------------------- Non-current liabilities Long-term portion of operating lease liabilities 1,935,709 2,499,990 Pension liability 694,959 583,426 Total non-current liabilities 2,630,668 3,083,416 --------------------- --------------------- Total liabilities 22,711,688 13,049,096 --------------------- --------------------- Commitments and contingencies (Note 15) Equity Class A Ordinary Shares: $0.0001 par value; 500,000,000 shares authorized; 63,046,025 shares issued and outstanding as of September 30, 2024; 60,466,453 shares issued and outstanding as of December 31, 2023 6,305 6,047 Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares authorized; 841,269 shares issued and outstanding as of September 30, 2024; 2,505,476 shares issued and outstanding as of December 31, 2023 84 251 Additional paid-in capital 675,343,443 609,969,236 Accumulated deficit (189,988,477) (116,657,472) Accumulated other comprehensive income 2,833,970 2,357,621 Total shareholders' equity 488,195,325 495,675,683 Noncontrolling interests 7,306,315 17,815,336 Total equity 495,501,640 513,491,019 --------------------- --------------------- Total liabilities and equity $ 518,213,328 $ 526,540,115 ===================== =====================

Peers Headlines